Biotech Values

[DewDiligence]

The 2-year clock on the second way of earning the $0.50/sh payment just started:

“(ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party's human C1 inhibitor product for two years from the later of the date of closing and the date that orphan exclusivity for Cinryze for the prophylaxis of HAE becomes effective.”